| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Y Wang, J M Egan, M Raygada, O Nadiv, J Roth, C Montrose-Rafizade. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology. vol 136. issue 11. 1995-11-27. PMID:7588224. |
treatment of cells with a transcription inhibitor, actinomycin d, demonstrated that elevated insulin mrna levels after a glp-1 exposure are mainly due to stabilization of the mrna. |
1995-11-27 |
2023-08-12 |
Not clear |
| Y Wang, J M Egan, M Raygada, O Nadiv, J Roth, C Montrose-Rafizade. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology. vol 136. issue 11. 1995-11-27. PMID:7588224. |
actinomycin d blunted the glp-1 effect on insulin release but did not affect glp-1 mediated elevation of insulin mrna. |
1995-11-27 |
2023-08-12 |
Not clear |
| Y Wang, J M Egan, M Raygada, O Nadiv, J Roth, C Montrose-Rafizade. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology. vol 136. issue 11. 1995-11-27. PMID:7588224. |
our study suggests that the mechanisms by which extended exposure of rin 1046-38 cells to glp-1 increases glucose-stimulated insulin secretion include significant up-regulation of glucose-sensing elements. |
1995-11-27 |
2023-08-12 |
Not clear |
| R Ritzel, C Orskov, J J Holst, M A Nauc. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia. vol 38. issue 6. 1995-10-13. PMID:7672496. |
it was the aim of this study to investigate whether subcutaneous glp-1 [7-36 amide] also has an influence on insulin and glucagon secretion, and which doses are required for significant effects. |
1995-10-13 |
2023-08-12 |
human |
| R Ritzel, C Orskov, J J Holst, M A Nauc. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia. vol 38. issue 6. 1995-10-13. PMID:7672496. |
blood was drawn for the measurement of glucose, insulin, c-peptide, glp-1 [7-36 amide], and glucagon using specific radioimmunoassays. |
1995-10-13 |
2023-08-12 |
human |
| D M Hargrove, N A Nardone, L M Persson, J C Parker, R W Stevenso. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism: clinical and experimental. vol 44. issue 9. 1995-10-12. PMID:7666800. |
in vitro, truncated glucagon-like peptides [glp-1(7-36)-amide and glp-1(7-37)] increase insulin secretion in a glucose-dependent manner, and desensitization to the action of glp-1(7-37) has been demonstrated acutely with high concentrations. |
1995-10-12 |
2023-08-12 |
rat |
| D M Hargrove, N A Nardone, L M Persson, J C Parker, R W Stevenso. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism: clinical and experimental. vol 44. issue 9. 1995-10-12. PMID:7666800. |
an intravenous (iv) infusion of glp-1(7-37) at 0.5, 5, or 50 pmol/min/kg during the second hour of a 2-hour 11-mmol/l hyperglycemic clamp in sprague-dawley rats produced a dose-related enhancement of the glucose-induced increase in plasma insulin concentration. |
1995-10-12 |
2023-08-12 |
rat |
| D M Hargrove, N A Nardone, L M Persson, J C Parker, R W Stevenso. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism: clinical and experimental. vol 44. issue 9. 1995-10-12. PMID:7666800. |
a 1-hour infusion of a submaximal dose of glp-1(7-37) (5 pmol/min/kg iv) in fasted and fed sprague-dawley rats produced small transient increases in plasma insulin (incremental increases above basal, 72 +/- 27 and 96 +/- 28 pmol/l, respectively) and decreases in plasma glucose (to levels > or = 5.2 mmol/l). |
1995-10-12 |
2023-08-12 |
rat |
| D M Hargrove, N A Nardone, L M Persson, J C Parker, R W Stevenso. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism: clinical and experimental. vol 44. issue 9. 1995-10-12. PMID:7666800. |
infusion of glp-1(7-37) (5 pmol/min/kg iv) during a hyperglycemic clamp at two sequentially increasing concentrations of glucose, 11 and 17 mmol/l, produced incremental increases in insulin of 600 and 1,200 pmol/l, respectively, relative to levels in clamped control rats. |
1995-10-12 |
2023-08-12 |
rat |
| D M Hargrove, N A Nardone, L M Persson, J C Parker, R W Stevenso. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism: clinical and experimental. vol 44. issue 9. 1995-10-12. PMID:7666800. |
similarly, infusion of glp-1(7-37) (5 pmol/min/kg iv) in hyperinsulinemic, hyperglycemic zucker diabetic fatty (zdf) rats produced a transitory increase in plasma insulin concentration and normalized the plasma glucose concentration. |
1995-10-12 |
2023-08-12 |
rat |
| J Rachman, R C Turne. Drugs on the horizon for treatment of type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association. vol 12. issue 6. 1995-09-28. PMID:7648818. |
the most promising new approach for enhancing insulin secretion has been suggested by the demonstration that pharmacological doses of glp-1 (7-36 amide), a natural enteric incretin hormone, improves pancreatic beta-cell and alpha-cell sensitivity to glucose and can induce normal basal glucose levels in diabetic man. |
1995-09-28 |
2023-08-12 |
Not clear |
| C Widmann, W Dolci, B Thoren. Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas. The Biochemical journal. vol 310 ( Pt 1). 1995-09-20. PMID:7646446. |
glucagon-like peptide-1 (glp-1) is the most potent stimulator of glucose-induced insulin secretion and its pancreatic beta-cell receptor is a member of a new subfamily of g-protein-coupled receptors which includes the receptors for vasoactive intestinal polypeptide, secretin and glucagon. |
1995-09-20 |
2023-08-12 |
Not clear |
| G G Holz, C A Leech, J F Habene. Activation of a cAMP-regulated Ca(2+)-signaling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like peptide-1. The Journal of biological chemistry. vol 270. issue 30. 1995-09-05. PMID:7543091. |
to investigate the ca2+ signaling pathways by which glp-1 may stimulate the secretion of insulin from pancreatic beta-cells, we examined its effects on the concentration of free intracellular ca2+ ([ca2+]i) while simultaneously determining what action it exerts on ion channel function. |
1995-09-05 |
2023-08-12 |
rat |
| K Owada, T Wasada, Y Miyazono, H Yoshino, S Hasumi, H Kuroki, K Yano, A Maruyama, K Kawai, Y Omor. Highly increased insulin secretion in a patient with postprandial hypoglycemia: role of glucagon-like peptide-1 (7-36) amide. Endocrine journal. vol 42. issue 2. 1995-09-01. PMID:7627258. |
the greatly enhanced insulin secretion leading to reactive hypoglycemia in this patient may therefore be attributed to the increased secretion of glp-1. |
1995-09-01 |
2023-08-12 |
Not clear |
| C Qualmann, M A Nauck, J J Holst, C Orskov, W Creutzfeld. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta diabetologica. vol 32. issue 1. 1995-08-18. PMID:7612912. |
glp-1 (7-36 amide) stimulates insulin and suppresses glucagon secretion in normal subjects and may, in pharmacological doses, normalize hyperglycaemia in type 2 diabetic patients. |
1995-08-18 |
2023-08-12 |
human |
| C Qualmann, M A Nauck, J J Holst, C Orskov, W Creutzfeld. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta diabetologica. vol 32. issue 1. 1995-08-18. PMID:7612912. |
the plasma concentration of glp-1 (7-36 amide) increased dose-dependently, but insulin secretion (insulin, c-peptide) was stimulated only marginally. |
1995-08-18 |
2023-08-12 |
human |
| C Qualmann, M A Nauck, J J Holst, C Orskov, W Creutzfeld. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta diabetologica. vol 32. issue 1. 1995-08-18. PMID:7612912. |
in conclusion, when plasma glucose concentrations are in the normal fasting range, glp-1 (7-36 amide) is not able to stimulate insulin secretion to a degree that causes hypoglycaemia. |
1995-08-18 |
2023-08-12 |
human |
| E Delgado, M A Luque, A Alcántara, M A Trapote, F Clemente, C Galera, I Valverde, M L Villanueva-Peñacarrill. Glucagon-like peptide-1 binding to rat skeletal muscle. Peptides. vol 16. issue 2. 1995-07-14. PMID:7784253. |
the specific binding was time and membrane protein concentration dependent, and displaceable by unlabeled glp-1(7-36)-amide with an id50 of 3 x 10(-9) m of the peptide; glp-1(1-36)-amide also competed, whereas glucagon and insulin did not. |
1995-07-14 |
2023-08-12 |
rat |
| K Kawai, C Yokota, S Ohashi, Y Watanabe, K Yamashit. Evidence that glucagon stimulates insulin secretion through its own receptor in rats. Diabetologia. vol 38. issue 3. 1995-06-26. PMID:7758872. |
since glucagon-like peptide-1 (7-36) amide (7-37) (glp-1) has been found to be a potent insulinotropic hormone, it has been postulated that glucagon stimulates insulin secretion from islet beta cells through the glp-1 receptor. |
1995-06-26 |
2023-08-12 |
rat |
| K Kawai, C Yokota, S Ohashi, Y Watanabe, K Yamashit. Evidence that glucagon stimulates insulin secretion through its own receptor in rats. Diabetologia. vol 38. issue 3. 1995-06-26. PMID:7758872. |
we therefore examined the effects of a glp-1 receptor antagonist, exendin (9-39) amide, on glucagon- or glp-1-stimulated insulin release from isolated perfused rat pancreas. |
1995-06-26 |
2023-08-12 |
rat |